hmmmm, you seem to be missing the whole point for the design of the phase 3 trial. By selecting disease stable patients who have responded favorably to chemo, the trial in essence self-selects those patients that are most likely to respond to rida. You're criticism may have been appropriate for the phase 2 trial but it simply doesn't hold water, imo, for the phase 3.
Dig a little deeper and I think you'll find that the sarcomas that are most likely to respond to chemo match up well with the rida response achieved in the phase 2. The info is out there but , just as you stated to another poster, "I will not do your homework for you."
